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ABSTRACT
Background: The impairment that pruritic skin diseases have on patient productivity at work, in the class-
room, and in daily activities is substantial and needs to be characterized. The objective of this study was to de-
termine how pruritic skin diseases impact patient productivity and quality of life (QOL), in order to improve the
measurement of these endpoints to allow the influence of treatment options including sedative and non-
sedative antihistamines to be analyzed.
Methods: The impact of pruritic skin diseases and the effect of antihistamine therapy on work, classroom, and
daily productivity were evaluated using the Work Productivity Assessment Index-Allergy Specific Question-
naire. The intensity of itch and patient QOL were assessed using a visual analogue scale and Skindex-16, re-
spectively.
Results: Pruritic skin diseases resulted in significant impairment of work, classroom, and daily productivity.
The severity of overall work impairment in atopic dermatitis (AD), urticaria, and prurigo was higher than for
other diseases analyzed. However, classroom activity was more adversely affected in patients with urticaria
relative to other diseases. All pruritic diseases in this study negatively impacted daily activity to a similar de-
gree. Impaired productivity was significantly improved in patients taking non-sedative antihistamines for 1
month, and the improvements correlated with the alleviation of itch and improved QOL.
Conclusions: These results indicate that pruritic skin diseases reduce patient productivity at work, in the
classroom, and during daily activities, and that non-sedative antihistamines may offer an advantage over seda-
tive antihistamines for alleviating certain negative consequences of these skin diseases.
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INTRODUCTION
The impaired quality of life (QOL) and diminished
work and classroom productivity of individuals with
pruritic skin diseases is a matter of public concern.1,2
Furthermore, estimates of the impact of pruritic skin
diseases on the economic loss in businesses and
school performance records have attracted a great
deal of interest worldwide.3,4 Similar unfavorable im-
pacts were identified for certain skin diseases, such
as chronic idiopathic urticaria, psoriasis, and chronic
hand dermatitis.5-8 The Work Productivity Assess-
ment Index (WPAI) is commonly used to determine
the impact of health and disease on certain parame-
ters related to patient productivity. According to the
WPAI, the estimated percent of overall work impair-
ment due to psoriasis, urticaria, and chronic hand
dermatitis is 15%, 25%, and 29%, respectively.5,6,8
Itching is a key characteristic of allergic skin dis-
eases that dramatically affects a patient’s quality of
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life.9,10 Thus, it is possible that itching alone would af-
fect patient performance in the work place. The al-
lergy specific WPAI (WPAI-AS) can be used to more
effectively assess productivity in these patients as
itching is a common symptom of allergy-related skin
diseases. Recently, we reported the effect of antihista-
mines on productivity of patients with pruritic skin
diseases using the WPAI-AS assessment question-
naire.11,12 On average, pruritic skin diseases impaired
overall workplace productivity, classroom productiv-
ity, and daily activity by 39%, 45%, and 42% at baseline,
respectively.12 Furthermore, non-sedative antihista-
mines (mainly fexofenadine) reduced the intensity of
itch and improved work productivity. In contrast,
sedative antihistamines failed to improve work pro-
ductivity, but significantly decreased itch intensity.12
However, the relative impact of different pruritic dis-
eases on work productivity has not been assessed. In
this report, the WPAI-AS evaluation system was ap-
plied to each subgroup of patients with different diag-
noses of pruritic skin diseases, and the degree of im-
pairment for each disease at baseline was compared
using a linear least-squares method. Furthermore,
itch severity and patient QOL were assessed using a
visual analogue scale (VAS) and Skindex-16, respec-
tively. Finally, after validating the relationships be-
tween these parameters, we propose a method to ap-
proach the treatment of pruritic skin disease that will
improve overall productivity in the workplace, in the
classroom, and in daily activities.
METHODS
PATIENTS AND STUDY DESIGN
This study was conducted between April, 2008 and
March, 2009. After obtaining approval from the Insti-
tutional Review Board (IRB), patients with pruritic
skin diseases (n = 216) from Osaka University Hospi-
tal or its affiliated hospitals, gave informed consent to
participate in this study. The final number of valid re-
sponses was n = 206 (male : female=93 : 113; mean
age ± SD: 52 ± 20 years). Patients with skin diseases
associated with underlying systemic diseases (e.g.,
serious liver disease, renal dysfunction, and blood
diseases), history of epilepsy, history of a previous
drug allergy, or women who were pregnant or lactat-
ing were excluded from this study. Participants re-
ceived no medical attention during the week before
study initiation. The selection of therapy for each pa-
tient, such as oral antihistamines versus external
medicine (e.g., steroid ointments, tacrolimus oint-
ments, or certain moisturizers), was left to the physi-
cian’s discretion (open-label trial). Fexofenadine (n =
72) and loratadine (n = 2), anti-histamines for which
the package insert contained no cautionary statement
regarding sedative actions, were categorized as “non-
sedative”. All other antihistamines were classified as
“sedative”.
STUDY INSTRUMENTS
The Skindex-16 quality-of-life instrument13 was used
to measure the effect of pruritic skin diseases on
QOL. The magnitude of the itch sensation was as-
sessed using a VAS (0-100, “0” indicates no-symptom,
and “100” indicates most severe symptom). Work and
classroom productivity were assessed with the WPAI-
AS instrument (score range, 0-100%; higher percent-
ages indicate higher productivity).11 Work productiv-
ity, classroom productivity, and daily activity impair-
ment (%I) were calculated by the effects of the pru-
ritic skin diseases on productivity while workingat-
tending class or other daily activities during the past
7 days. The percentage of workclassroom time
missed (%TM = TMTW) was calculated by the num-
ber of workclassroom hours missed due to allergy
(TM) and the usual number of hours workedattend-
ing class (TW). Finally, the percentage overall impair-
ment was calculated as follows: %TM + ( [100 - %TM]
× I%) = % overall impairment.11 These instruments
were patient-administered before (baseline) and 1
month after treatment initiation.
STATISTICAL ANALYSIS
The one-sample t-test was used for analysis of differ-
ences between two groups. Pearson’s product-
moment correlation coefficient was used to deter-
mine the significance of correlations between two pa-
rameters (Table 1, 2). To examine the significance of
the contingency between the certain categorical data,
Fisher’s exact test (for evaluating the significance be-
tween the two kinds of classifications) and Cochran-
Mantel-Haenszel general association statistics (for
evaluating more than 3 kinds of classifications) were
performed (Table 3). The bias of evaluative conse-
quences to one variable was analyzed using univari-
ate analysis (Table 4). A linear least-squares method
was used to evaluate the degree of impairment in
each disease at baseline. Because heterogeneity of
starting values was inevitable, the effect measures il-
lustrated in Figure 1 were evaluated using linear
models. The results and confidence intervals for the
improvement variations were compared visually for
each parameter using a forest plot. Improvement vari-
ations (change ratios) were calculated as follows:
change ratio = (evaluated value 1 month after the in-
itiation of treatment-baseline value)(baseline value).
In all tests, values of P < 0.05 were considered statisti-
cally significant.
RESULTS
STUDY POPULATION CHARACTERISTICS
A total of 216 patients with pruritic skin disease en-
tered the study, and data from 206 patients (average
age of 52 ± 20 years) who completed the study were
used for analysis. Company employees and part-time
workers represented 48% of the patients (n = 99), and
retired seniors and unemployed individuals ac-
Novel Outcomes in Pruritic Skin Disease
Allergology International Vol 59, No4, 2010 www.jsaweb.jp 347
Table 1 Corelations between baseline parameters and patient outcomes
Corelations to baseline patient parameters
[P-value, Pearson’ scoeficient of corelation (r), n]
Activity impairmentSkindex-16 scoreItch VASAlergic pruritic skin diseases(AD and urticaria)
P < 0.001
(r = 0.6712, n = 52)
P < 0.001
(r = 0.5674, n = 51)
NS
(r = 0.2443, n = 52)
Overal work productivity impairment
NS
(r = 0.1833, n = 14)
NS
(r = 0.0915, n = 13)
NS
(r = 0.1948, n = 14)
Overal classroom productivity impairment
-
-
P < 0.001
(r = 0.7051, n = 84)
P = 0.006
(r = 0.2893, n = 89)
Activity impairment
Non-alergic skin diseases
(Al other excluding AD and urticaria)
P < 0.001
(r = 0.8584, n = 47)
P < 0.001
(r = 0.4813, n = 46)
NS
(r = 0.2904, n = 44)
Overal work productivity impairment
P = 0.0014
(r = 0.9986, n = 4)
NS
(r = 0.7963, n = 4)
NS
(r = 0.2604, n = 4)
Overal classroom productivity impairment
-
-
P < 0.001
(r = 0.5170, n = 109)
P < 0.001
(r = 0.3332, n = 107)
Activity impairment
NS, not statisticaly significant; vs., versus.
Table 2 Corelative relationships between antihistamine treatment groups and the improvement ratio of itch VAS scores to 
Skindex-16, overal work productivity impairment, and activity impairment
Corelations to baseline patient improvement ratios by treatment group
[P-value, Pearson’ scoeficient of corelation (r), n]
Sedative AHNon-sedative AH
NSP < 0.001Skindex-16 score vs. itch VAS
(r = 0.2360, n = 99)(r = 0.5769, n = 69)
NSP = 0.0042Overal work productivity impairment vs. itch VAS
(r = 0.2462, n = 46)(r = 0.4539, n = 38)
NSP = 0.0046Activity impairment vs. itch VAS
(r = 0.1203, n = 92)(r = 0.3448, n = 66)
NS, not statisticaly significant; AH, anti-histamines; VAS, visual analogue scale.
counted for 43% (n = 89). Students made up a rela-
tively small fraction of the study group (n = 18, 9%).
Patients diagnosed with eczemadermatitis had the
highest representation (36%) among participants, fol-
lowed in decreasing order by patients with urticaria,
atopic dermatitis (AD), pruritus, prurigo, and psoria-
sis (Table 5).
ASSESSMENT OF WORK, CLASSROOM, AND
ACTIVITY IMPAIRMENT
Table 6 shows the baseline work, classroom, and
daily activity WPAI-AS productivity scores. Due to the
relatively small sample size of each disease group,
statistically significant differences in impairment be-
tween disease groups were not detected (Fig. 2).
However, the results indicate that the overall impair-
ment of work, classroom, and daily activity productiv-
ity tended to be larger in the atopic dermatitis, ec-
zemadermatitis, and urticaria disease groups (Fig.
2). There were also some interesting group-specific
observations. Prurigo showed higher overall impair-
ment of work productivity and daily activity. Individu-
als with urticaria had relatively higher percentages of
impairment of overall classroom productivity than
that observed in other skin diseases. Daily activity
was impaired at high percentages for individuals with
AD.
CORRELATION BETWEEN PRODUCTIVITY IM-
PAIRMENT AND SKINDEX-16, OR LOSS OF
DAILY LIFE PRODUCTIVITY
To check the validity of the assessment procedures in
this study, we looked for correlations between im-
paired productivity at work, in the classroom, and in
daily activities. In addition, correlations between over-
all activity impairment, the magnitude of itch sensa-
tion as assessed by VAS, and QOL measures as as-
sessed by Skindex-16 were analyzed (Table 1). As
shown in Table 1, correlation analyses were divided
between allergic (atopic dermatitis and urticaria) and
non-allergic skin diseases (all other diagnosis
groups). Results specific for allergic skin diseases in-
dicated that impairment in overall work productivity
showed a positive correlation with the itch VAS,
Skindex-16, and the impairment in daily activity. A
correlation between impairment in overall classroom
Murota H et al.
348 Allergology International Vol 59, No4, 2010 www.jsaweb.jp
Table 3 Distribution of patient characteristics in the sedative and non-sedative antihistamine treatment groups
P-value †
Sedative AHNon-sedative AH
Background factors
%n%n
0.183
45.85556.842<50
Age
54.26543.232≥50
0.183
40.04850.037Male
Gender
60.07250.037Female
0.515
18.32227.020AD
Disease
37.54535.126Ec/der
27.53321.616Urticaria
16.72016.212Other
0.017
42.55160.845Worker
Occupation  8.31010.8 8Student
49.25928.421Other
1.000
61.77462.246<5 years
Duration of disease
28.33428.421≥5 years
† Diferences in the distribution of patients between sedative and non-sedative antihistame groups was determined by the Fisher’ sexact 
test for age, gender, and duration of disease and by the Cochran-Mantel-Haenszel general association statistic for disease diagnostic group 
and occupation. AH, antihistamines; AD, atopic dermatitis; Ec/der, eczema/dermatitis.
Table 4 Impact of background factors on the improvement of WPAI-AS score
Impact of patient characteristics on overal productivity impairment (P-value)
Patient characteristics
Daily activity impairmentOveral classroom impairmentOveral work impairment
0.35560.29860.345 Age
0.26150.54640.4454Gender
0.41180.53490.0646Disease
0.25280.47930.0053Duration of disease: <5 years, ≥5 years
0.5097N/AN/AOccupation: worker, student, other
N/A, not applicable.
productivity and itch VAS, Skindex-16 score, and ac-
tivity impairment was not observed for the allergic
skin diseases (Table 1). However, in the allergic skin
disease subgroup there was a positive correlation be-
tween the impairment in daily activity and the magni-
tude of itch and Skindex-16 scores.
Similar analyses were performed on the subgroup
of patients with all other skin disease diagnoses ex-
cept atopic dermatitis and urticaria. This group was
designated the non-allergic skin disease group even
though varying causative conditions including aller-
gic and non-allergic mechanisms could be responsi-
ble for symptoms related to eczemadermatitis. As
shown in Table 1, the correlation profile of this sub-
group was very similar to that of the allergic skin dis-
ease subgroup with one major difference. There was
a significant correlation between overall classroom
productivity and activity impairment in the non-
allergic skin disease subgroup (Table 1).
IMPACT OF ANTIHISTAMINES ON PATIENT
OUTCOMES
Patients were treated with non-sedative antihista-
mines (n = 74), sedative antihistamines (n = 121), or
external medication (n = 11) for a duration of 1 month
(Table 7). The patient characteristics in the
physician-assigned treatment groups of sedative and
non-sedative antihistamines were all well-matched
with the exception of occupation (Table 3). We previ-
ously reported that the impaired productivity in pru-
ritic skin diseases was significantly improved in pa-
tients taking non-sedative antihistamines.12 Interest-
ingly, for patients taking non-sedative antihistamines
in this study, the improvement ratio as assessed us-
ing the VAS score showed a significant correlation
with improvements in the Skindex-16 score, the re-
duction in overall work productivity impairment, and
the reduction in daily activity impairment. No signifi-
cant correlations were found among patients taking
sedative antihistamines (Table 2).
To eliminate the bias for starting value dispersion,
the effects of non-sedative and sedative antihista-
mines on overall work productivity, daily activity, and
overall classroom productivity were corrected by
grouping according to background factors or baseline
value using the linear least-squares methods (Fig.
1A). Results indicated that non-sedative antihista-
mines produced greater overall improvements in pro-
Novel Outcomes in Pruritic Skin Disease
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Fig. 1 A. The impact of antihistamines on overal work productivity impairment, activity productivity impairment, and 
overal classroom productivity impairment per-certain parameters of pruritic skin diseases. Changes in the evaluated 
value of certain parameters from baseline were adjusted with background factors and the initial value (a linear model).  
Results are shown in a forest plot. Horizontal lines indicate 95% confidence intervals. The rhomboid or square dot on cen-
ter of the horizontal line indicates the point estimate. Significance is indicated by horizontal lines that do not overlap with 
the vertical line of least mean square = 0. NA, not applicable. B. Comparison of overal work impairment (amount of chan-
ge) adjusted by background factor (disease duration).
Antihistamines Characteristic
Non-sedative Age <50
A
Sedative
Non-sedative ≧50
Sedative
Non-sedative Gender Male
Sedative
Non-sedative Female
Sedative
Non-sedative ADDisease
Sedative
Eczema
dermatitis Non-sedative
Sedative
Non-sedative Urticaria
Sedative
Non-sedative Other
Sedative
Non-sedative Occupation Worker
Sedative
Student Non-sedative
Sedative
Non-sedative Other
Sedative
Non-sedative <5 yearsDuration of
Disease Sedative 
Non-sedative ≥5 years
Sedative
Daily activity impairment Overall classroom impairmentOverall work impairment 
NA
NA
NA
NA
NA
NA
NA
NANA
NA
NA
NA
least mean square
exacerbationimprovement exacerbationimprovement exacerbationimprovement
-80 -40 0 40 -80 -40 0 40 40-80 -40 0
-40 0-10-20 -30 10 least mean square
Non-sedative antihistamine
B
Sedative antihistamine
improvement exacerbation
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Table 5 Characteristics of patient population by pruritic skin disease diagnostic group
Average duration of disease (yrs ± SD)Average age (yrs ± SD)FemaleMale(n)Disease
17.1 ± 13.233.7 ± 10.1222143Atopic dermatitis
3.1 ± 8.161.9 ± 17.8423375Eczema/dermatitis
 5.4 ± 10.147.3 ± 16.3331750Urticaria
3.4 ± 3.664.3 ± 18.1 5 914Pruritus
2.1 ± 1.559.8 ± 16.6 2 6 8Prurigo
1.1 ± 1.449.3 ± 19.6 3 4 7Psoriasis
10.8 ± 14.954.7 ± 18.2 6 3 9Others †
† Includes patients with systemic lupus erythematodes, tinea pedis, toxicoderma, polymorphic light eruption, von Recklinghausen disease, 
tuberous sclerosis, scabies, bulous pemphigoid, and lupus erythematodes.
Table 6 Baseline WPAI-AS productivity scores (Mean ± SD)
OthersPsoriasisPrurigoPruritusUrticariaEc/DerAD
(n = 6)(n = 3)(n = 5)(n = 2) (n = 21) (n = 31) (n = 31)Work
23.3 ± 29.426.7 ± 25.236.0 ± 18.220.0 ± 0   33.8 ± 25.841.0 ± 24.838.7 ± 26.3Work productivity impairment
02.2 ± 3.812.2 ± 21.7010.6 ± 26.8 2.6 ± 10.3 4.9 ± 11.4Work time missed
23.3 ± 29.428.9 ± 21.742.9 ± 24.820.0 ± 0   41.8 ± 29.541.3 ± 25.240.4 ± 26.8Overal work productivity impairment
(n = 1)(n = 1)(n = 0)(n = 1)(n = 6)(n = 1)(n = 8)Classroom
10 0-063.3 ± 15.150.041.3 ± 25.3Classroom productivity impairment
00-014.5 ± 17.800Classroom time missed
10 0-070.1 ± 10.550.041.3 ± 25.3Overal classroom productivity
(n = 9)(n = 7)(n = 8) (n = 14) (n = 46) (n = 72) (n = 43)Activity
34.4 ± 29.244.3 ± 28.846.3 ± 22.037.9 ± 20.137.6 ± 26.441.8 ± 23.050.2 ± 26.9Activity impairment
AD, atopic dermatitis; Ec/Der, Eczema/Dermatitis; SD, Standard deviation.
ductivity in patients with skin diseases than sedative
antihistamines (Fig. 1A). Non-sedative antihistamines
significantly improved work productivity under al-
most all background conditions with the exception of
disease duration. Sedative antihistamines only had a
significant impact on the subpopulation of patients
that were male or those that had a diagnosis of ec-
zemadermatitis (Fig. 1A).
The duration of disease was the only baseline pa-
tient characteristic that could significantly influence
or bias the outcomes seen from administration of an-
tihistamines (Table 4). Therefore, we compared the
amount of change in the overall work impairment in
the sedative and non-sedative antihistamine treat-
ment groups after adjusting for the baseline duration
of disease (Fig. 1B). These results confirmed that
non-sedative antihistamines significantly improved
the overall work impairment, while sedative antihista-
mines did not (Fig. 1B). Evaluation of impact of anti-
histamines on daily activity impairment and overall
classroom impairment also demonstrate the superior-
ity of non-sedative antihistamines over sedative anti-
histamines (Fig. 1A). Interestingly, sedative antihista-
mines failed to improve overall classroom productiv-
ity in all the patient population groups analyzed (Fig.
1A).
THE EFFECT OF ANTIHISTAMINES ON ATOPIC
DERMATITIS
The effect of antihistamines on atopic dermatitis is
still controversial.14,15 Therefore, the treatment ef-
fects specifically for patients with atopic dermatitis (n =
43) were analyzed independently from other diagnos-
tic groups (Fig. 3). As expected, treatment with anti-
histamines significantly reduced itch intensity in
atopic dermatitis, while external medicines were inef-
fective (Fig. 3A). No differences were found between
patients taking non-sedative versus sedative antihista-
mines (Fig. 3A). The impact of all treatments on the
Skindex-16 QOL measure was similar to that for the
itch VAS, with a significant effect for all antihista-
mines, but not for topical medications (Fig. 3B). Both
non-sedative, and sedative antihistamines improved
overall work impairment without statistical signifi-
cance (Fig. 3C). Alternatively, the non-sedative anti-
histamine significantly reduced activity productivity
impairment, whereas the trend towards improvement
seen with sedative antihistamines did not reach statis-
tical significance (Fig. 3D). These patients were pre-
scribed concomitant external medications, but there
were no remarkable differences between the non-
sedative and sedative antihistamines treatment
groups (Fig. 3E).
Novel Outcomes in Pruritic Skin Disease
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Table 7 Number of patients from each skin disease diagnostic group assigned to indicated treatments
OthersPsoriasisPrurigoPruritusUriticariaEc/DerADnSedation
511 5142620 72NSFexofenadine
000 0 2 0 0  2NSLoratadine
133 21818 8 53SOlopatadine
020 0 0 3 3  8SEpinastine
001 0 0 6 2  9SCetirizine
100 1 1 7 1 11SEbastine
100 1 7 5 5 19SOther 2nd generation
012 2 7 6 3 21S1st generation
101 3 1 4 1 11-External medicine
97814507543206-Total
AH, anti-histamines; NS, non-sedative; S, sedative; AD, atopic dermatitis; Ec/Der, Eczema/Dermatitis.
Fig. 2 Forest plots demonstrating the degree of impairment in each disease at baseline was evaluated using a linear 
least-squares method. Horizontal lines represent 95% confidence intervals. The rhomboid dot on the center of horizontal 
line indicates the point estimate. NA, not applicable.
0 20 40 60 80 100 0 20 40 60 80 100 0 20 40 60 80 100 
Overall work impairment Overall classroom impairment Daily activity impairment
severely affected
least mean square
AD
NA
Ec/Der
Urticaria
Pruritus
Prurigo
Psoriasis
Others
DISCUSSION
This study demonstrates that allergic skin diseases
may have detrimental effects on productivity at work,
in the classroom, and during daily activity. Previous
reports demonstrated that allergic rhinitis impaired
mean overall productivity at work, in the classroom,
and in daily activity by ratios of 27-48%, 33-47%, and
42-51%, respectively.16-19 In the present study, work
performance and daily activities were highly and simi-
larly impaired in patients with allergic skin diseases.
However, WPAI-AS baseline scores in our study were
slightly high relative to previous reports of WPAI (un-
identified version) baseline scores for chronic idi-
opathic urticaria, psoriasis, and chronic hand dermati-
tis.5,6,8 It is not currently clear why the present study
generated different WPAI baseline scores, but further
investigation is warranted.
According to the WPAI-AS values for the various
pruritic skin diseases, the impairments in classroom
productivity and overall classroom productivity were
higher for patients with urticaria (Fig. 2). To clarify
the reason why urticaria affected classroom produc-
tivity, cases of students with urticaria were analyzed
independently for correlations with certain parame-
ters (data not shown). Only the Skindex-16 was sig-
nificantly associated with classroom impairment in
this group (P = 0.0075, r = 0.9282, n = 6). Presumably,
urticaria may impair a student’s classroom productiv-
ity by negatively impacting their QOL.
In previous reports, WAPI scores of overall work
impairment in patients with psoriasis were lower than
those for patients with chronic idiopathic urticaria
and chronic hand dermatitis.5,6,8 Pearce and col-
leagues6 discussed the observation that QOL meas-
ures did not exhibit the same trend as WPAI score in
Murota H et al.
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Fig. 3 The impact of antihistamines on (A) itch VAS, (B) skindex-16 score, (C) overal work productivity 
impairment, and (D) daily activity productivity impairment in atopic dermatitis. The data of baseline assess-
ment (dark gray bar) and post treatment assessment (light gray bar) are shown as mean ± SD. **Statisti-
caly significant improvement compared with the data of baseline assessment (P < 0.001), *P < 0.01. NA, 
not applicable; AH, antihistamines. (E) Concomitant external medicine for cases with atopic dermatitis. 
“Other”includes vitamin D3 or non-steroidal anti-inflammatory ointment.
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patients with psoriasis, and indicated that estimating
the impact of psoriasis on social life seemed to be dif-
ficult. Indeed, as the number of patients with psoria-
sis was low in this study, which may indicate that our
data are not representative of the general population
of patients with psoriasis.
Concerning WPAI-AS scores in patients with atopic
dermatitis, the total loss of daily activities was rela-
tively higher than for patients with other skin dis-
eases (Table 6, Fig. 2). It has been said that the inten-
sity of itch might be increased in a relaxed environ-
ment, such as coming home or at nighttime.20 In sup-
port of this, daily activity in patients with atopic der-
matitis or pruritus was severely impaired compared
with the impairment in overall work productivity (Ta-
ble 6). Thus, daily activity may be highly susceptible
to impairment in patients with atopic dermatitis and
pruritus.
The differences between patients taking non-
sedative versus sedative antihistamines was also ad-
dressed. As previously reported, sedative antihista-
mines failed to reduce work productivity impairment
despite decreasing itch VAS values and Skindex-16
measures.12 Impaired performance as an adverse ef-
fect of sedative antihistamines may be a major factor
in these divergent results. In fact, in patients treated
with sedative antihistamines, the improvement ratio
for itch VAS scores did not significantly correlate
with either the Skindex-16 QOL measure, the re-
duced impairment in overall work productivity, or the
reduced impairment in daily activity (Table 2). Addi-
tionally, the extent of impairment in overall work pro-
ductivity can be predicted by the Skindex-16 meas-
ures (Table 1). Nevertheless, clinicians should keep
in mind that they could overestimate the effect of
sedative antihistamines to improve on work produc-
tivity by relying solely on patient itch-intensity and
QOL values. For these reasons, non-sedative antihis-
tamines have substantial value in the treatment of pa-
tients with pruritic skin diseases.
However, the criteria for selecting antihistamines
differ from disease to disease and vary worldwide. It
is well known that non-sedative antihistamines, but
not sedative antihistamines, are recommended as
first-line agents for urticaria treatment.21-25 In con-
trast, many previous published reviews, guidelines,
and position papers on the care of atopic dermatitis
state that the antihistamines are no more than a sup-
portive management for pruritus, and their sedative
properties offer an advantage for reducing the magni-
tude of itch in atopic dermatitis.14,15,26,27 Thus, there
is a tendency worldwide to recommend sedative anti-
histamines for the treatment of atopic dermatitis with
intense itch or sleep disturbance.14,15,26 Our data chal-
lenge this trend, since non-sedative antihistamines re-
duced the impairments in daily activity in patients
with atopic dermatitis, while sedative antihistamines
were ineffective (Fig. 1A, 3). Accordingly, the criteria
for selecting antihistamines in certain skin diseases
should be reconsidered.
Limitations of this study include the number of pa-
tients in each group and the potential influences of
the adverse global economic conditions. Nonethe-
less, this report may highlight a new goal in the treat-
ment of pruritic skin diseases and provide a rationale
for shifting the choice of treatment options to non-
sedative antihistamines.
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